MedChemExpress

®

Apamin TFA

Cat. No.:	HY-P0256A					
Molecular Formula:	C ₈₁ H ₁₃₂ F ₃ N ₃₁ O ₂₆ S ₄					
Molecular Weight:	2141.36					
Sequence Shortening:	CNCKAPETALCARRCQQH-NH2 (Disulfide bridge: Cys1-Cys11;Cys3-Cys15)			CNCKAPETALCARRCQQH-NH2 (Disulfide bridge: Cys1-Cys11; Cys3-Cys15) (TFA salt)		
Target:	Potassium Channel					
Pathway:	Membrane ⁻	Transport	er/Ion Channel			
Storage:	Sealed storage, away from moisture					
	Powder	-80°C	2 years			
		-20°C	1 year			
	* In solvent	:-80°C,6	months; -20°C, 1 month (sealed storage, away from moisture)			

SOLVENT & SOLUBILITY

In Vitro H ₂ O : 50 mg/	H ₂ O : 50 mg/mL (23.35 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	0.4670 mL	2.3350 mL	4.6699 mL		
		5 mM	0.0934 mL	0.4670 mL	0.9340 mL		
		10 mM	0.0467 mL	0.2335 mL	0.4670 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent Solubility: 100 mg	one by one: PBS ;/mL (46.70 mM); Clear solution; Need	d ultrasonic				

FA (Apamine TFA) is an 18 amino acid peptide neurotoxin found in apitoxin (bee venom), is known as a specifically blocker of Ca ²⁺ -activated K ⁺ (SK) channels and exhibits anti-inflammatory and anti-fibrotic activity ^[1] .
FA (Apamine TFA) is an 18 amino acid peptide neurotoxin found in apitoxin (bee venom), is known as a specifically blocker of Ca ²⁺ -activated K ⁺ (SK) channels and exhibits anti-inflammatory and anti-fibrotic activity ^[1] .
ə[1]
D.5-2 μg/mL; 24 hours; HSC-T6 cells) treatment markedly reduces the expression of α-SMA in the TGF-β1-induced ells. Apamin treatment abrogats the activation of p-Smad2/3 and Smad4 induced by TGF-β1 ^[1] . not independently confirmed the accuracy of these methods. They are for reference only. Blot Analysis ^[1]
e

	Concentration:	0.5 μg/mL, 1 μg/mL and 2 μg/mL				
	Incubation Time:	24 hours				
	Result:	Markedly reduced the expression of α -SMA in the TGF- β 1-induced HSC-T6 cells. Abrogated the activation of p-Smad2/3 and Smad4 induced by TGF- β 1.				
In Vivo	Apamin (0.1 mg/kg; intr liver injury and proinfla expression of fibrogenic MCE has not independe	Apamin (0.1 mg/kg; intraperitoneal injection; twice a week; for 4 weeks; C57BL/6 male mice) treatment results in decreased liver injury and proinflammatory cytokine levels. Apamin suppresses the deposition of collagen, proliferation of BECs and expression of fibrogenic genes in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				
	Animal Model:	8-week-old C57BL/6 male mice (20-25 g) with DDC feeding ^[1]				
	Dosage:	0.1 mg/kg				
	Administration:	Intraperitoneal injection; twice a week; for 4 weeks				
	Result:	Resulted in decreased liver injury and proinflammatory cytokine levels. Suppressed the deposition of collagen, proliferation of BECs and expression of fibrogenic genes in the DDC-fed mice.				

CUSTOMER VALIDATION

• Cell Calcium. 2022 Jun;104:102571.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Kim JY, et al. Apamin suppresses biliary fibrosis and activation of hepatic stellate cells. Int J Mol Med. 2017 May;39(5):1188-1194.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA